SanBio Group has signed an agreement with Hitachi Chemical’s U.S.-based contract manufacturing subsidiary, Hitachi Chemical Advanced Therapeutics Solutions (HCATS). They will manufacture SB623, a proprietary regenerative medicine product under development by SanBio. Under the agreement, late stage clinical products and commercial products of SB623 for the U.S. and Japanese markets will be manufactured using Hitachi Chemical’s global facilities. SanBio is developing and pursuing th...